Related Experiment Video
Updated: Jun 15, 2026
08:27
Large-Scale Multi-Omics Genome-Wide Association Studies (Mo-GWAS): Guidelines for Sample Preparation and Normalization
Published on: July 27, 2021
Genome-wide association studies in atherothrombosis
1Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Università degli Studi di Milano, Department of Medicine and Medical Specialities, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Luigi Villa Foundation, via Pace 9, 20122, Milan, Italy. luca.lotta@unimi.it
European Journal of Internal Medicine
|March 9, 2010
Summary
Genetic research has identified over 430 genomic regions linked to complex diseases like atherothrombosis. These findings, from numerous genome-wide association studies, pave the way for understanding genetic predispositions to conditions such as heart attack and stroke.
Area of Science:
- Genetics
- Cardiovascular Medicine
- Genomics
Background:
- Atherothrombotic diseases result from complex genetic and environmental interactions.
- The genetic underpinnings of these conditions were previously not well understood.
- Recent advancements in DNA analysis and human genome characterization have enabled comprehensive genetic studies.
Purpose of the Study:
- To review the progress in understanding the genetic basis of atherothrombotic diseases.
- To highlight the identification of genetic variants influencing disease predisposition.
- To discuss the implications of these genetic discoveries for future clinical applications.
Main Methods:
- Utilizing data from over 400 genome-wide association studies (GWAS).
- Analyzing large-scale human genome variability data.
- Synthesizing findings on common genetic variants associated with complex diseases.
Main Results:
- Identification of more than 430 genomic regions associated with complex disease predisposition.
- Established significant associations between common genetic variants and atherothrombotic diseases.
- Demonstrated the power of GWAS in uncovering genetic influences on disease risk.
Conclusions:
- Significant progress has been made in characterizing the genetic basis of atherothrombotic diseases.
- Genetic discoveries offer new insights into the predisposition to myocardial infarction and ischemic stroke.
- Current genetic findings are poised for translation into clinical applications.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...